REVIEW PAPER
Association between cigarette smoking and plasma concentration of efavirenz: a systematic review
1
Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
2
Department of Pharmacy, Hospital Kulim, Kedah, Malaysia
Submission date: 2019-12-23
Acceptance date: 2020-09-01
Publication date: 2021-04-12
HIV & AIDS Review 2021;20(1):10-16
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Statistics show that prevalence of smokers is higher among human immunodeficiency virus-positive patients. Efavirenz is still widely used in resource-limited setting around the world. In view of overlapping metabolic pathways between cigarette smoking and efavirenz, it is suggested that poorer treatment outcome among smokers with HIV might be in some way associated with abnormal plasma concentration of efavirenz.
Material and methods:
Comprehensive search of the literature was performed using PubMed Central, PubMed/Medline, Cochrane Review, Science Direct, Springer Link, Oxford Academic, and Lippincott Williams & Wilkins journals.
Results:
A total of 157 articles were chosen, out of which 8 met eligibility criteria and were reviewed. Lower efavirenz plasma concentration were found in 5 articles, where genetic polymorphism was the major significant co-variate. Only 2 studies described smoking as significantly associated with lower efavirenz plasma concentration.
Conclusions:
Smoking was found to be associated with a lower efavirenz plasma concentration, especially in population with genetic polymorphism. Future research is required with better methodological design, and subjects with genetic polymorphism need to be excluded, to further investigate the causal relationship of smoking status and efavirenz plasma concentration.
Statistics show that prevalence of smokers is higher among human immunodeficiency virus-positive patients. Efavirenz is still widely used in resource-limited setting around the world. In view of overlapping metabolic pathways between cigarette smoking and efavirenz, it is suggested that poorer treatment outcome among smokers with HIV might be in some way associated with abnormal plasma concentration of efavirenz.
Material and methods:
Comprehensive search of the literature was performed using PubMed Central, PubMed/Medline, Cochrane Review, Science Direct, Springer Link, Oxford Academic, and Lippincott Williams & Wilkins journals.
Results:
A total of 157 articles were chosen, out of which 8 met eligibility criteria and were reviewed. Lower efavirenz plasma concentration were found in 5 articles, where genetic polymorphism was the major significant co-variate. Only 2 studies described smoking as significantly associated with lower efavirenz plasma concentration.
Conclusions:
Smoking was found to be associated with a lower efavirenz plasma concentration, especially in population with genetic polymorphism. Future research is required with better methodological design, and subjects with genetic polymorphism need to be excluded, to further investigate the causal relationship of smoking status and efavirenz plasma concentration.
REFERENCES (38)
2.
Pacek LR, Cioe PA. Tobacco use, use disorders, and smoking cessation interventions in persons living with HIV. Curr HIV/AIDS Rep 2015; 12: 413-420.
3.
Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc 2011; 8: 313-319.
4.
Mdodo R, Frazier EL, Dube SR, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med 2015; 162: 335-344.
5.
Mdege ND, Shah S, Ayo-Yusuf OA, Hakim J, Siddiqi K. Tobacco use among people living with HIV: analysis of data from Demographic and Health Surveys from 28 low-income and middle-income countries. Lancet Glob Health 2017; 5: e578-e592.
7.
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71-75.
8.
Bednasz CJ, Venuto CS, Ma Q, et al. Efavirenz therapeutic range in HIV-1 treatment-naive participants. Ther Drug Monit 2017; 39: 596-603.
9.
Hile SJ, Feldman MB, Alexy ER, Irvine MK. Recent tobacco smoking is associated with poor HIV medical outcomes among HIV-.
11.
O’Cleirigh C, Valentine SE, Pinkston M, et al. The unique challenges facing HIV-positive patients who smoke cigarettes: HIV viremia, art adherence, engagement in HIV care, and concurrent substance use. AIDS Behav 2014; 19: 178-185.
12.
Hicham T, Ilyas E, Tarik H, et al. Risk factors associated with unsuppressed viral load in HIV-1 infected patients at the first antiretroviral therapy in Morocco. Int J Mycobacteriology 2019; 8: 113-117.
13.
George S, McGrath N, Oni T. The association between a detectable HIV viral load and non-communicable diseases comorbidity in HIV positive adults on antiretroviral therapy in Western Cape, South Africa. BMC Infect Dis 2019; 19: 348.
14.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available at: https://clinicalinfo.hiv.gov/s....
15.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-94.
16.
National Institutes of Health. Study Quality Assessment Tools National Heart, Lung, and Blood Institute (NHLBI). Available at: https://www.nhlbi.nih.gov/heal.... 2014 (Accessed: 21.03.2018).
17.
Guo F, Cheng X, Hsieh E, et al. Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study. HIV Med 2018; 19: 440-451.
18.
Swart M, Evans J, Skelton M, et al. An expanded analysis of pharmacogenetics determinants of Efavirenz response that includes 3’-UTR single nucleotide polymorphisms among black South African HIV/AIDS patients. Front Genet 2016; 6: 356.
19.
Olagunju A, Siccardi M, Amara A, et al. CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients. Ther Drug Monit 2014; 36: 734-738.
20.
Cortes CP, Siccardi M, Chaikan A, Owen A, Zhang G, la Porte CJL. Correlates of efavirenz exposure in chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Ther Drug Monit 2013; 35: 78-83.
21.
Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet Genomics 2013; 23: 415-427.
22.
Read TRH, Carey D, Mallon P, et al. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. AIDS 2009; 23: 2222-2223.
23.
Gandhi M, Benet LZ, Bacchetti P, et al. Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr 2009; 50: 482-491.
24.
Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61: 914-918.
25.
McDonagh EM, Lau JL, Alvarellos ML, Altman RB, Klein TE. PharmGKB summary: Efavirenz pathway, pharmacokinetics. Pharmacogenet Genomics 2015; 25: 363-376.
26.
Hedrich WD, Hassan HE, Wang H. Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B 2016; 6: 413-425.
27.
Lamba V, Yasuda K, Lamba JK, et al. PXR (NR1I2): Splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 2004; 199: 251-265.
28.
Washio I, Maeda M, Sugiura C, et al. Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes. Drug Metab Dispos 2011; 39: 1-3.
29.
Swart M, Whitehorn H, Ren Y, Smith P, Ramesar RS, Dandara C. PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC Med Genet 2012; 13: 112.
30.
Leger P, Chirwa S, Turner M, et al. Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race. Pharmacogenet Genomics 2016; 26: 473-480.
31.
Wyen C, Hendra H, Siccardi M, et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother 2011; 66: 2092-2098.
32.
Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf 2013; 12: 841-846.
33.
Winston A, Amin J, Clarke A, et al. Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial. Clin Infect Dis 2015; 60: 1026-1032.
34.
Gounden V, van Niekerk C, Snyman T, George JA. Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 2010; 7: 32.
35.
Amin J, Becker S, Belloso W, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis 2015; 15: 793-802.
36.
López-Cortés LF, Ruiz-Valderas R, Marín-Niebla A, Pascual-Carrasco R, Rodríguez-Díez M, Lucero-Muñoz MJ. Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations. J Acquir Immune Defic Syndr 2005; 39: 551-556.
37.
Santos GM, Tan J, Turner C, Raymond HF. Demographic, behavioral, and social characteristics associated with smoking and vaping among men who have sex with men in San Francisco. Am J Mens Health 2019; 13: 1557988319847833.
38.
Leventhal AM, Stone MD, Andrabi N, et al. Association of e-cigarette vaping and progression to heavier patterns of cigarette smoking. JAMA 2016; 316: 1918-1920.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
